Theravectys Announces $20M Funding Round
THERAVECTYS,
the world leading pioneer in lentiviral vector technology, announced
today a fully subscribed $20M funding round. This funding will be used
to progress the Theravectys pipeline by driving several vaccine
candidates, including their COVID vaccine, into phase 1 and 1-2 clinical
trials.
More info >> |